STOCK TITAN

Rhythm Pharmaceuticals Inc. - RYTM STOCK NEWS

Welcome to our dedicated news page for Rhythm Pharmaceuticals (Ticker: RYTM), a resource for investors and traders seeking the latest updates and insights on Rhythm Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Rhythm Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Rhythm Pharmaceuticals's position in the market.

Rhea-AI Summary
Rhythm Pharmaceuticals will host a live conference call to report its Q3 2023 financial results and provide a corporate update. The CEO will also participate in a fireside chat at the Stifel Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.34%
Tags
conferences earnings
-
Rhea-AI Summary
Rhythm Pharmaceuticals announces data presentations showing sustained and deepened weight loss in patients with severe obesity caused by rare MC4R pathway diseases
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Rhythm Pharmaceuticals grants inducement equity grants to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Rhythm Pharmaceuticals announces acceptance of six abstracts for presentation at The Obesity Society’s Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.24%
Tags
none
-
Rhea-AI Summary
Rhythm Pharmaceuticals announces multiple presentations at ESPE 2023, highlighting the impact of setmelanotide on metabolic syndrome risk and the frequency of obesity-related gene variants in pediatric patients with rare melanocortin-4 receptor pathway diseases. 20.4% of individuals with early-onset severe obesity carry a variant in MC4R pathway-related genes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
none
-
Rhea-AI Summary
Rhythm Pharmaceuticals receives positive opinion from EMA for setmelanotide as a treatment for acquired hypothalamic obesity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.77%
Tags
Rhea-AI Summary
Rhythm Pharmaceuticals grants inducement equity grants to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Rhythm Pharmaceuticals cancels participation in H.C. Wainwright conference due to travel conflicts. CEO to participate in fireside chat at Morgan Stanley conference on Sept. 11.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
none
-
Rhea-AI Summary
Rhythm Pharmaceuticals announces approval of new ICD-10 diagnosis code for Bardet-Biedl Syndrome (BBS), improving disease awareness and access to therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
none
Rhea-AI Summary
Rhythm Pharmaceuticals to present at three investor conferences in September
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
conferences
Rhythm Pharmaceuticals Inc.

Nasdaq:RYTM

RYTM Rankings

RYTM Stock Data

2.43B
44.99M
0.52%
112.26%
16.19%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Boston

About RYTM

rhythm pharmaceuticals inc. is a biotechnology company located in 855 boylston street, 11th floor, boston, ma, united states.